Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 110 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $990,065 | -39.4% | 81,959 | -18.5% | 0.00% | – |
| Q1 2024 | $1,634,423 | +642.2% | 100,518 | +211.3% | 0.00% | – |
| Q4 2023 | $220,205 | -19.3% | 32,288 | -19.7% | 0.00% | – |
| Q2 2023 | $272,924 | +124.5% | 40,195 | +65.7% | 0.00% | – |
| Q1 2023 | $121,568 | -62.6% | 24,265 | -63.6% | 0.00% | – |
| Q4 2022 | $325,257 | +82.7% | 66,651 | +438.6% | 0.00% | – |
| Q3 2022 | $178,000 | -75.4% | 12,375 | -72.3% | 0.00% | – |
| Q4 2021 | $724,000 | +38.4% | 44,673 | +144.0% | 0.00% | – |
| Q3 2021 | $523,000 | +139.9% | 18,311 | +154.2% | 0.00% | – |
| Q1 2021 | $218,000 | -78.6% | 7,204 | -65.0% | 0.00% | -100.0% |
| Q4 2020 | $1,020,000 | +200.0% | 20,607 | +132.5% | 0.00% | – |
| Q3 2020 | $340,000 | +10.0% | 8,864 | +23.9% | 0.00% | – |
| Q2 2020 | $309,000 | – | 7,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,194,278 | $84,238,000 | 6.25% |
| Burrage Capital Management LLC | 123,025 | $4,723,000 | 3.73% |
| MPM BioImpact LLC | 337,291 | $12,949,000 | 3.12% |
| First Light Asset Management, LLC | 608,193 | $23,349,000 | 2.39% |
| Cormorant Asset Management, LP | 1,397,700 | $53,658,000 | 2.06% |
| SPHERA FUNDS MANAGEMENT LTD. | 396,521 | $15,222,000 | 1.50% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 801 | $33,000 | 0.61% |
| Artal Group S.A. | 285,028 | $10,942,000 | 0.27% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 298,213 | $11,448,000 | 0.24% |
| Virtus ETF Advisers LLC | 7,309 | $281,000 | 0.15% |